KaliVir Immunotherapeutics: Funding, Investors & Team (Sep 2026)
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs.
KaliVir Immunotherapeutics has raised $14.1M across 2 funding rounds on record, the most recent a Series A of $14.0M announced in Aug 2026.
That round is above the $4.8M median round size for Health Care companies tracked on FundedIQ over the last two years.
KaliVir Immunotherapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2026.
KaliVir Immunotherapeutics Funding Rounds
KaliVir Immunotherapeutics raised $100k in a Series A announced in Mar 2022.
4.4 years later, a Series A of $14.0M was announced in Aug 2026.
KaliVir Immunotherapeutics Investors
7 investors are recorded in total; the 5 named above are those the record identifies.
KaliVir Immunotherapeutics Founders and Leadership Team
Contact details for the KaliVir Immunotherapeutics team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →KaliVir Immunotherapeutics Funding Compared to Other Health Care Startups
KaliVir Immunotherapeutics' latest round of $14.0M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like KaliVir Immunotherapeutics in Health Care and Pittsburgh
Companies Similar to KaliVir Immunotherapeutics
Thyme Care is an oncology solution that integrates patients and providers, working with health plans to…
https://metriport.com
There are too many reasons why Healthcare is unaffordable in the U.S, but one of the largest is waste. Up to…
Serif Health provides healthcare price intelligence and contract management solution.
Switchboard Health provides virtual care solutions to payers, health systems, employers, and at-risk…
Astek Diagnostics has designed a system that helps doctors choose the right antibiotics for patients…
TECLens is developing a crosslinking technology that can effectively address vision problems in both healthy…
Healthcare Shares operates as a crowdfunding portal for the transformative medical innovations of the future.
Gradient Health collaborates with medical data providers worldwide to assemble diseases and conditions for AI…
Happy Health is a mission-driven technology company committed to transforming mental health awareness through…
Leal Therapeutics creates new treatments for patients.
Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical…
KaliVir Immunotherapeutics Funding FAQs
What does KaliVir Immunotherapeutics do?
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs.
How much funding has KaliVir Immunotherapeutics raised?
KaliVir Immunotherapeutics has raised $14.1M across 2 rounds on record. The most recent is a Series A of $14.0M announced in Aug 2026.
When did KaliVir Immunotherapeutics last raise funding?
KaliVir Immunotherapeutics' most recent funding round on record is a Series A of $14.0M, announced in Aug 2026.
Who has invested in KaliVir Immunotherapeutics?
Investors on record for KaliVir Immunotherapeutics include Flexus Partners, Premier Partners, Nextrans, Company K Partners, SV Investment Corp. FundedIQ records 7 investors in total.
Who is the CEO of KaliVir Immunotherapeutics?
Helena Chaye is listed as CEO at KaliVir Immunotherapeutics.
Where is KaliVir Immunotherapeutics headquartered?
KaliVir Immunotherapeutics is based in Pittsburgh, Pennsylvania, United States.
How many employees does KaliVir Immunotherapeutics have?
KaliVir Immunotherapeutics is in the 11-50 employee band.
When was KaliVir Immunotherapeutics founded?
KaliVir Immunotherapeutics was founded in 2019.
How does KaliVir Immunotherapeutics' funding compare to other Health Care startups?
KaliVir Immunotherapeutics' latest round of $14.0M is above the $4.8M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's KaliVir Immunotherapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for KaliVir Immunotherapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.